PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
NCT ID: NCT05756244
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
825 participants
OBSERVATIONAL
2023-04-04
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)
NCT03530332
Prospective Study in Pregnant Women With Hypercoagulopathy
NCT00215969
Management of Postpartum Preeclampsia
NCT05775744
Development and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP)
NCT05586334
Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial
NCT05878899
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of:
1. Objectively confirmed VTE (DVT, superficial vein thrombosis \[SVT\], PE or unusual site thrombosis) diagnosed during the current pregnancy;
2. Objectively confirmed VTE diagnosed in a prior pregnancy;
3. Objectively confirmed VTE diagnosed when not pregnant;
4. Inherited or acquired thrombophilia requiring anticoagulation.
* Receiving any dose or type of LMWH during the antepartum period
Exclusion Criteria
* Unable to provide or declined consent.
* Home or birthing centre planned delivery.
18 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leslie Skeith, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Isabelle Malhamé, MD
Role: PRINCIPAL_INVESTIGATOR
McGill University
Kinga Malinowski, MD
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Hospital
Durham, North Carolina, United States
Foothills Medical Centre
Calgary, Alberta, Canada
Royal Alexandra Hospital
Edmonton, Alberta, Canada
BC Women's Hospital and Health Centre
Vancouver, British Columbia, Canada
St. Boniface Hospital
Winnipeg, Manitoba, Canada
McMaster University Medical Centre
Hamilton, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Montfort Hospital
Ottawa, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
CHU Sainte-Justine
Montreal, Quebec, Canada
The Sir Mortimer B. Davis Jewish General Hospital
Montreal, Quebec, Canada
Aarhus University Hospital
Aarhus, , Denmark
Le Centre Hospitalier Universitaire of Saint-Etienne
Saint-Etienne, , France
Hopitaux universitaires de Geneve
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jens Fuglsang, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB21-0795
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.